Transcriptome, proteome, and metabolome in dyssynchronous heart failure and CRT

Andreas S. Barth, Khalid Chakir, David A. Kass, Gordon F. Tomaselli

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Cardiac resynchronization therapy reduces morbidity and mortality in patients with symptomatic systolic heart failure (New York Heart Association class III or IV) and ventricular conduction delay. The current review focuses on how high-throughput technologies including gene expression profiling and proteomics have helped in our understanding of the pathophysiology of electromechanical dyssynchrony and the molecular mechanisms by which cardiac resynchronization therapy (CRT) exerts its beneficial effects. Comparing gene expression changes in earlyactivated anterior vs. late-activated lateral left ventricular myocardium in a large animal model of dyssynchronous heart failure, we demonstrated a profound effect of electromechanical dyssynchrony on the regional cardiac transcriptome, as changes in gene expression were primarily observed in the early-activated anterior left ventricular myocardium. This increase in regional heterogeneity of gene expression within the left ventricle was reversed by CRT. Specifically, CRT remodeled transcripts with metabolic and cell signaling function, which was corroborated by protein data. In addition, high-throughput or "omic" techniques also hold great promise to identify key pathways and biomarkers that are regulated differentially in CRT responders vs. nonresponders.

Original languageEnglish (US)
Pages (from-to)180-187
Number of pages8
JournalJournal of Cardiovascular Translational Research
Volume5
Issue number2
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

Cardiac Resynchronization Therapy
Metabolome
Proteome
Transcriptome
Heart Failure
Gene Expression
Myocardium
Systolic Heart Failure
Gene Expression Profiling
Proteomics
Heart Ventricles
Animal Models
Biomarkers
Technology
Morbidity
Mortality
Proteins

Keywords

  • Cardiac resynchronization therapy
  • Functional genomics
  • Gene expression
  • Heart failure
  • Proteomics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Genetics
  • Genetics(clinical)
  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Transcriptome, proteome, and metabolome in dyssynchronous heart failure and CRT. / Barth, Andreas S.; Chakir, Khalid; Kass, David A.; Tomaselli, Gordon F.

In: Journal of Cardiovascular Translational Research, Vol. 5, No. 2, 01.04.2012, p. 180-187.

Research output: Contribution to journalReview article

@article{adabf07abeb84dcfa772029da470dd40,
title = "Transcriptome, proteome, and metabolome in dyssynchronous heart failure and CRT",
abstract = "Cardiac resynchronization therapy reduces morbidity and mortality in patients with symptomatic systolic heart failure (New York Heart Association class III or IV) and ventricular conduction delay. The current review focuses on how high-throughput technologies including gene expression profiling and proteomics have helped in our understanding of the pathophysiology of electromechanical dyssynchrony and the molecular mechanisms by which cardiac resynchronization therapy (CRT) exerts its beneficial effects. Comparing gene expression changes in earlyactivated anterior vs. late-activated lateral left ventricular myocardium in a large animal model of dyssynchronous heart failure, we demonstrated a profound effect of electromechanical dyssynchrony on the regional cardiac transcriptome, as changes in gene expression were primarily observed in the early-activated anterior left ventricular myocardium. This increase in regional heterogeneity of gene expression within the left ventricle was reversed by CRT. Specifically, CRT remodeled transcripts with metabolic and cell signaling function, which was corroborated by protein data. In addition, high-throughput or {"}omic{"} techniques also hold great promise to identify key pathways and biomarkers that are regulated differentially in CRT responders vs. nonresponders.",
keywords = "Cardiac resynchronization therapy, Functional genomics, Gene expression, Heart failure, Proteomics",
author = "Barth, {Andreas S.} and Khalid Chakir and Kass, {David A.} and Tomaselli, {Gordon F.}",
year = "2012",
month = "4",
day = "1",
doi = "10.1007/s12265-011-9339-2",
language = "English (US)",
volume = "5",
pages = "180--187",
journal = "Journal of Cardiovascular Translational Research",
issn = "1937-5387",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Transcriptome, proteome, and metabolome in dyssynchronous heart failure and CRT

AU - Barth, Andreas S.

AU - Chakir, Khalid

AU - Kass, David A.

AU - Tomaselli, Gordon F.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Cardiac resynchronization therapy reduces morbidity and mortality in patients with symptomatic systolic heart failure (New York Heart Association class III or IV) and ventricular conduction delay. The current review focuses on how high-throughput technologies including gene expression profiling and proteomics have helped in our understanding of the pathophysiology of electromechanical dyssynchrony and the molecular mechanisms by which cardiac resynchronization therapy (CRT) exerts its beneficial effects. Comparing gene expression changes in earlyactivated anterior vs. late-activated lateral left ventricular myocardium in a large animal model of dyssynchronous heart failure, we demonstrated a profound effect of electromechanical dyssynchrony on the regional cardiac transcriptome, as changes in gene expression were primarily observed in the early-activated anterior left ventricular myocardium. This increase in regional heterogeneity of gene expression within the left ventricle was reversed by CRT. Specifically, CRT remodeled transcripts with metabolic and cell signaling function, which was corroborated by protein data. In addition, high-throughput or "omic" techniques also hold great promise to identify key pathways and biomarkers that are regulated differentially in CRT responders vs. nonresponders.

AB - Cardiac resynchronization therapy reduces morbidity and mortality in patients with symptomatic systolic heart failure (New York Heart Association class III or IV) and ventricular conduction delay. The current review focuses on how high-throughput technologies including gene expression profiling and proteomics have helped in our understanding of the pathophysiology of electromechanical dyssynchrony and the molecular mechanisms by which cardiac resynchronization therapy (CRT) exerts its beneficial effects. Comparing gene expression changes in earlyactivated anterior vs. late-activated lateral left ventricular myocardium in a large animal model of dyssynchronous heart failure, we demonstrated a profound effect of electromechanical dyssynchrony on the regional cardiac transcriptome, as changes in gene expression were primarily observed in the early-activated anterior left ventricular myocardium. This increase in regional heterogeneity of gene expression within the left ventricle was reversed by CRT. Specifically, CRT remodeled transcripts with metabolic and cell signaling function, which was corroborated by protein data. In addition, high-throughput or "omic" techniques also hold great promise to identify key pathways and biomarkers that are regulated differentially in CRT responders vs. nonresponders.

KW - Cardiac resynchronization therapy

KW - Functional genomics

KW - Gene expression

KW - Heart failure

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=84866127616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866127616&partnerID=8YFLogxK

U2 - 10.1007/s12265-011-9339-2

DO - 10.1007/s12265-011-9339-2

M3 - Review article

C2 - 22311562

AN - SCOPUS:84866127616

VL - 5

SP - 180

EP - 187

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

SN - 1937-5387

IS - 2

ER -